Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety trial of flat-dose nivolumab plus ipilimumab in non-small cell lung cancer
2016-002621-10Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of nivolumab and ipilimumab in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Bristol Myers Squibb. Primary endpoint: High-grade treatment-related select and immune-mediated adverse events. Started Sep 2016; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2016-002621-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002621-10.